Investigating monoclonal antibody aggregation using a combination of H/DX-MS and other biophysical measurements

Journal of Pharmaceutical Sciences

Volumn 102, Issue 12, 2013, Pages 4315-4329

  Iacob, Roxana E ^a   Bou Assaf, George M ^b   Makowski, Lee ^a,c   Engen, John R ^a   Berkowitz, Steven A ^b   Houde, Damian ^b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b BIOGEN   (United States)

^c Northeastern University   (United States)

Author keywords

Antibody dimerization; Calorimetry (DSC); Chromatography; Domain swapping; Electrophoresis; Hydrogen deuterium exchange mass spectrometry (H DX MS); Protein aggregation; Protein structure; Small angle X ray solution scattering (SAXS)

Indexed keywords

DIMER; MAB 1 PROTEIN; MAB 2 PROTEIN; MONOCLONAL ANTIBODY; MONOMER; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY STRUCTURE; ARTICLE; CHEMICAL ANALYSIS; DIFFERENTIAL SCANNING CALORIMETRY; DIMERIZATION; GEL PERMEATION CHROMATOGRAPHY; HEAVY CHAIN; HINGE REGION; HYDROGEN DEUTERIUM EXCHANGE MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; NONHUMAN; PEPTIDE MAPPING; POLYACRYLAMIDE GEL ELECTROPHORESIS; TANDEM MASS SPECTROMETRY; THERMOSTABILITY; ULTRACENTRIFUGATION;

ANTIBODY DIMERIZATION; CALORIMETRY (DSC); CHROMATOGRAPHY; DOMAIN SWAPPING; ELECTROPHORESIS; HYDROGEN-DEUTERIUM EXCHANGE MASS SPECTROMETRY (H/DX-MS); PROTEIN AGGREGATION; PROTEIN STRUCTURE; SMALL-ANGLE X-RAY SOLUTION SCATTERING (SAXS);

ANIMALS; ANTIBODIES, MONOCLONAL; CALORIMETRY, DIFFERENTIAL SCANNING; CHO CELLS; CRICETULUS; DISULFIDES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; MASS SPECTROMETRY; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; SCATTERING, SMALL ANGLE; X-RAY DIFFRACTION;

EID: 84888198342     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23754     Document Type: Article

References (72)

1. Beck A, Wurch T, Bailly C, Corvaia N,. 2010. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10 (5): 345-352.
2. Reichert JM,. 2012. Marketed therapeutic antibodies compendium. mAbs 4 (3): 413-415.
3. Reichert JM,. 2012. Which are the antibodies to watch in 2012? mAbs 4 (1): 1-3.
4. Nimmerjahn F, Ravetch, JV,. 2008. Fc gamma receptors as regulators of immune responses. Nat Rev Immunol 8: 34-47.
5. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M,. 2002. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416 (6880): 507-511.
6. Rosenberg AS,. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8 (3): E501-E507.
7. Wang W,. 2005. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 289 (1-2): 1-30.
8. Beck A, Wagner-Rousset E, Ayoub D, Van Dorsselaer A, Sanglier-Cianferani S,. 2012. Characterization of therapeutic antibodies and related products. Anal Chem 85 (2): 715-736.
9. Finke JM, Roy M, Zimm BH, Jennings PA,. 2000. Aggregation events occur prior to stable intermediate formation during refolding of interleukin 1beta. Biochemistry 39 (3): 575-583.
10. Philo JS, Arakawa T,. 2009. Mechanisms of protein aggregation. Curr Pharm Biotechnol 10 (4): 348-351.
11. Costantino HR, Langer R, Klibanov AM,. 1994. Solid-phase aggregation of proteins under pharmaceutically relevant conditions. J Pharm Sci 83 (12): 1662-1669.
12. Jahn TR, Radford SE,. 2008. Folding versus aggregation: Polypeptide conformations on competing pathways. Arch Biochem Biophys 469 (1): 100-117.
13. Chi EY, Krishnan S, Kendrick BS, Chang BS, Carpenter JF, Randolph TW,. 2003. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci 12 (5): 903-913.
14. Wang X, Das TK, Singh SK, Kumar S,. 2009. Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies. mAbs 1 (3): 254-267.
15. Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riekel C, Grothe R, Eisenberg D,. 2005. Structure of the cross-beta spine of amyloid-like fibrils. Nature 435 (7043): 773-778.
16. Wiltzius JJ, Sievers SA, Sawaya MR, Cascio D, Popov D, Riekel C, Eisenberg D,. 2008. Atomic structure of the cross-beta spine of islet amyloid polypeptide (amylin). Protein Sci 17 (9): 1467-1474.
17. Jefferis R,. 2009. Recombinant antibody therapeutics: The impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 30 (7): 356-362.
18. Jefferis R,. 2009. Glycosylation of antibody therapeutics: Optimisation for purpose. Methods Mol Biol 483: 223-238.
19. Houde D, Arndt J, Domeier W, Berkowitz S, Engen JR,. 2009. Characterization of IgG1 conformation and conformational dynamics by hydrogen/deuterium exchange mass spectrometry. Anal Chem 81 (7): 2644-2651.
20. Houde D, Peng Y, Berkowitz SA, Engen JR,. 2010. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics 9 (8): 1716-1728.
21. Matsumiya S, Yamaguchi Y, Saito J, Nagano M, Sasakawa H, Otaki S, Satoh M, Shitara K, Kato K,. 2007. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol 368 (3): 767-779.
22. Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R,. 2000. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: Properties of a series of truncated glycoforms. Mol Immunol 37 (12-13): 697-706.
23. Mizushima T, Yagi H, Takemoto E, Shibata-Koyama M, Isoda Y, Iida S, Masuda K, Satoh M, Kato K,. 2011. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells 16 (11): 1071-1080.
24. Allaire M, Yang L,. 2011. Biomolecular solution X-ray scattering at the National Synchrotron Light Source. J Synchrotron Radiat 18: 41-44.
25. Wales TE, Fadgen KE, Gerhardt GC, Engen JR,. 2008. High-speed and high-resolution UPLC separation at zero degrees Celsius. Anal Chem 80 (17): 6815-6820.
26. Wales TE, Engen JR,. 2006. Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom Rev 25 (1): 158-170.
27. Englander SW, Kallenbach NR,. 1983. Hydrogen exchange and structural dynamics of proteins and nucleic acids. Q Rev Biophys 16 (4): 521-655.
28. Burkitt W, O'Connor G,. 2008. Assessment of the repeatability and reproducibility of hydrogen/deuterium exchange mass spectrometry measurements. Rapid Commun Mass Spectrom 22 (23): 3893-3901.
29. Plumb RS, Johnson KA, Rainville P, Smith BW, Wilson ID, Castro-Perez JM, Nicholson JK,. 2006. UPLC/MS(E); a new approach for generating molecular fragment information for biomarker structure elucidation. Rapid Commun Mass Spectrom 20 (13): 1989-1994.
30. Kavan D, Man P,. 2011. MSTools-Web based application for visualization and presentation of HXMS data. Int J Mass Spectrom 302 (1-3): 53-58.
31. Seeliger D, de Groot BL,. 2010. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des 24 (5): 417-422.
32. Vermeer AW, Norde W,. 2000. The thermal stability of immunoglobulin: Unfolding and aggregation of a multi-domain protein. Biophys J 78 (1): 394-404.
33. Garber E, Demarest SJ,. 2007. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun 355 (3): 751-757.
34. Ionescu RM, Vlasak J, Price C, Kirchmeier M,. 2008. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 97 (4): 1414-1426.
35. Tischenko VM, Abramov VM, Zav'yalov VP,. 1998. Investigation of the cooperative structure of Fc fragments from myeloma immunoglobulin G. Biochemistry 37 (16): 5576-5581.
36. Rathore YS, Solanki AK, Dhoke RR, Ashish,. 2011. SAXS data analysis and modeling of tetravalent neutralizing antibody CD4-IgG2 -/+ HIV-1 gp120 revealed that first two gp120 bind to the same Fab arm. Biochem Biophys Res Commun 415 (4): 680-685.
37. Ashish, Solanki AK, Boone CD, Krueger JK,. 2010. Global structure of HIV-1 neutralizing antibody IgG1 b12 is asymmetric. Biochem Biophys Res Commun 391 (1): 947-951.
38. Volkov VV, Kayushina RL, Lapuk VA, Shtykova EV, Varlamova EY, Malfois M, Svergun DI,. 2003. Solution structures of human immunoglobulins IgG and IgM and rheumatoid factor IgM-RF. Crystallogr Rep 48 (1): 98-105.
39. Lilyestrom WG, Shire SJ, Scherer TM,. 2012. Influence of the cosolute environment on IgG solution structure analyzed by small-angle X-ray scattering. J Phys Chem B 116 (32): 9611-9618.
40. Houde D, Demarest SJ,. 2011. Fine details of IGF-1R activation, inhibition, and asymmetry determined by associated hydrogen /deuterium-exchange and peptide mass mapping. Structure 19 (6): 890-900.
41. Houde D, Berkowitz SA, Engen JR,. 2011. The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies. J Pharm Sci 100 (6): 2071-2086.
42. Bobst CE, Abzalimov RR, Houde D, Kloczewiak M, Mhatre R, Berkowitz SA, Kaltashov IA,. 2008. Detection and characterization of altered conformations of protein pharmaceuticals using complementary mass spectrometry-based approaches. Anal Chem 80 (19): 7473-7481.
43. Engen JR., 2009. Analysis of protein conformation and dynamics by hydrogen/deuterium exchange MS. Anal Chem 81 (19): 7870-7875.
44. Engen JR, Smith DL,. 2001. Investigating protein structure and dynamics by hydrogen exchange MS. Anal Chem 73 (9): 256A-265A.
45. Smith DL, Deng Y, Zhang Z,. 1997. Probing the non-covalent structure of proteins by amide hydrogen exchange and mass spectrometry. J Mass Spectrom 32 (2): 135-146.
46. Zhang Z, Smith DL,. 1993. Determination of amide hydrogen exchange by mass spectrometry: A new tool for protein structure elucidation. Protein Sci 2 (4): 522-531.
47. Katta V, Chait BT,. 1991. Conformational changes in proteins probed by hydrogen-exchange electrospray-ionization mass spectrometry. Rapid Commun Mass Spectrom 5 (4): 214-217.
48. Klein M, Haeffner-Cavaillon N, Isenman DE, Rivat C, Navia MA, Davies DR, Dorrington KJ,. 1981. Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region. Proc Natl Acad Sci USA 78 (1): 524-528.
49. Silva JC, Gorenstein MV, Li GZ, Vissers JP, Geromanos SJ,. 2006. Absolute quantification of proteins by LCMSE: A virtue of parallel MS acquisition. Mol Cell Proteomics 5 (1): 144-156.
50. Fang J, Rand KD, Beuning PJ, Engen JR,. 2011. False EX1 signatures caused by sample carryover during HX MS analyses. Int J Mass Spectrom 302 (1-3): 19-25.
51. Kiese S, Papppenberger A, Friess W, Mahler HC,. 2008. Shaken, not stirred: Mechanical stress testing of an IgG1 antibody. J Pharm Sci 97 (10): 4347-4366.
52. Remmele RL Jr., Callahan WJ, Krishnan S, Zhou L, Bondarenko PV, Nichols AC, Kleemann GR, Pipes GD, Park S, Fodor S, Kras E, Brems DN,. 2006. Active dimer of Epratuzumab provides insight into the complex nature of an antibody aggregate. J Pharm Sci 95 (1): 126-145.
53. Yoo EM, Wims LA, Chan LA, Morrison SL,. 2003. Human IgG2 can form covalent dimers. J Immunol 170 (6): 3134-3138.
54. Schauenstein E, Schauenstein K, Dachs F, Reiter M, Leitsberger A, Weblacher M, Maninger K, Horejsi H, Steinschifter W, Hirschmann C, Felsner P,. 1996. Reactive disulfide bonds in immunoglobulin G. A unique feature in serum proteins of different species. Biochem Mol Biol Int 40 (3): 433-446.
55. Huh JH, White AJ, Brych SR, Franey H,. 2013. The identification of free cysteine residues within antibodies and a potential role for free cysteine residues in covalent aggregation because of agitation stress. J Pharm Sci 102 (6): 1701-1711.
56. Sahin E, Grillo AO, Perkins MD, Roberts CJ,. 2010. Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. J Pharm Sci 99 (12): 4830-4848.
57. Sahin E, Weiss WFt, Kroetsch AM, King KR, Kessler RK, Das TK, Roberts CJ,. 2012. Aggregation and pH-temperature phase behavior for aggregates of an IgG2 antibody. J Pharm Sci 101 (5): 1678-1687.
58. Jaskolski M., 2011. 3D domain swapping-implications for conformational disorders and ways of control. Bio Technologia 92: 34-44.
59. West AP Jr., Galimidi RP, Foglesong CP, Gnanapragasam PN, Huey-Tubman KE, Klein JS, Suzuki MD, Tiangco NE, Vielmetter J, Bjorkman PJ,. 2009. Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency. J Virol 83 (1): 98-104.
60. Feige MJ, Walter S, Buchner J,. 2004. Folding mechanism of the CH2 antibody domain. J Mol Biol 344 (1): 107-118.
61. Zheng K, Bantog C, Bayer R,. 2011. The impact of glycosylation on monoclonal antibody conformation and stability. mAbs 3 (6): 568-576.
62. Zhang A, Singh SK, Shirts MR, Kumar S, Fernandez EJ,. 2012. Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange. Pharm Res 29 (1): 236-250.
63. Dall'Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H,. 2006. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol 177 (2): 1129-1138.
64. Oi VT, Vuong TM, Hardy R, Reidler J, Dangle J, Herzenberg LA, Stryer L,. 1984. Correlation between segmental flexibility and effector function of antibodies. Nature 307 (5947): 136-140.
65. Michaelsen TE, Aase A, Westby C, Sandlie I,. 1990. Enhancement of complement activation and cytolysis of human IgG3 by deletion of hinge exons. Scand J Immunol 32 (5): 517-528.
66. Redpath S, Michaelsen T, Sandlie I, Clark MR,. 1998. Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52. Immunology 93 (4): 595-600.
67. Majumdar R, Manikwar P, Hickey JM, Samra HS, Sathish HA, Bishop SM, Middaugh CR, Volkin DB, Weis DD,. 2013. Effects of salts from the hofmeister series on the conformational stability, aggregation propensity, and local flexibility of an IgG1 monoclonal antibody. Biochemistry 52 (19): 3376-3389.
68. Manikwar P, Majumdar R, Hickey JM, Thakkar SV, Samra HS, Sathish HA, Bishop SM, Middaugh CR, Weis DD, Volkin DB,. 2013. Correlating excipient effects on conformational and storage stability of an IgG1 monoclonal antibody with local dynamics as measured by hydrogen/deuterium-exchange mass spectrometry. J Pharm Sci 102 (7): 2136-2151.
69. Bennett MJ, Choe S, Eisenberg D,. 1994. Domain swapping: Entangling alliances between proteins. Proc Natl Acad Sci USA 91 (8): 3127-3131.
70. Orlikowska M, Jankowska E, Kolodziejczyk R, Jaskolski M, Szymanska A,. 2011. Hinge-loop mutation can be used to control 3D domain swapping and amyloidogenesis of human cystatin C. J Struct Biol 173 (2): 406-413.
71. Rousseau F, Schymkowitz J, Itzhaki LS,. 2012. Implications of 3D domain swapping for protein folding, misfolding and function. Adv Exp Med Biol 747: 137-152.
72. Orlikowska M, Jankowska E, Kolodziejczyk R, Jaskolski M, Szymanska A,. 2011. Hinge-loop mutation can be used to control 3D domain swapping and amyloidogenesis of human cystatin C. J Struct Biol 173 (2): 406-413.